Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

SHAREHOLDER ALERT – NWL FLKS: The Law Offices of Vincent Wong Notifies Investors of Important Class Action Deadlines

NWL, SLRX

NEW YORK, June 26, 2018 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Newell Brands Inc. (NYSE:NWL)
Lead Plaintiff Deadline: August 20, 2018                
Class Period: February 6, 2017 and January 24, 2018

The complaint alleges that the Company’s retail channel was loaded with extremely high levels of unsold Newell product; contrary to defendants’ representations, the build-up of Newell inventory in the retail channel was due to Company-specific rather than macroeconomic reasons; as a result of the unusually high levels of unsold inventory in the retail channel, Newell was exposed to a heightened risk that it would experience slower sales growth in future periods; and undisclosed managerial and cultural differences in the legacy Newell and Jarden businesses had created significant discord that was having a material adverse effect on the Company’s operating performance.

Get additional information: http://www.wongesq.com/pslra-c/newell-brands-inc?wire=3.

Flex Pharma, Inc. (NASDAQ:FLKS)
Lead Plaintiff Deadline: August 20, 2018                
Class Period: November 6, 2017 and June 12, 2018

The complaint alleges that the Company overstated the viability and approval prospects for its product candidate FLX-787 for the treatment of amyotrophic lateral sclerosis and Charcot-Marie-Tooth disease; and as a result, Flex Pharma's public statements were materially false and misleading at all relevant times.

Get additional information: http://www.wongesq.com/pslra-c/flex-pharma-inc?wire=3.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

Primary Logo



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today